All In Biotech

Free tool

FAERS Monitor: Apretude

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215499 or its brand name (Apretude, Cabotegravir). Reports on generic versions are filed under their own applications.

Reports

8,201

Serious

1,642

20% of reports

Hospitalization

363

Death reported

105

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • product dose omission issue1,128
  • off label use1,050
  • injection site pain943
  • viral load increased434
  • pain414
  • virologic failure270
  • pyrexia259
  • inappropriate schedule of product administration257
  • product use in unapproved therapeutic environment254
  • pathogen resistance251
  • product complaint240
  • drug ineffective236
  • fatigue194
  • injection site nodule188
  • product storage error185

Reports by year received

View as table
YearReports
20162
201716
20187
201922
202038
2021253
2022997
20231,934
20242,656
20251,752
2026524

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,958 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product use in unapproved therapeutic environmentSignal2541051.3910.0188,337
viral load increasedSignal434322.6292.7123,355
virologic failureSignal270135.5120.134,124
pathogen resistanceSignal25172.664.217,173
injection site noduleSignal18844.638.67,830
product complaintSignal24024.521.65,345
product dose omission issueSignal1,1289.99.39,077
injection site painSignal9437.97.45,748
product storage errorSignal1855.44.7665
inappropriate schedule of product administrationSignal2573.73.2498
off label useSignal1,0503.12.91,533
pyrexia2591.91.7115
pain4141.71.6130
fatigue1940.60.641
drug ineffective2360.50.4160

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.